We specialize in modeling and simulation with the goal of enhancing drug development. We offer solutions from preclinical-to-clinical translation, dose selection , population selection and product differentiation through our state-of-the-art modeling methodologies. Our staff is well-versed in the areas of PK/PD, PBPK and QSP. Though we support all disease areas, we have particular experience in ophthalmology as well as diabetes indications.
We routinely perform pharmacometric analyses, including preclinical and population-based PK analysis, exposure-response analysis or population-based PK/PD modeling.
Physiologically-based pharmacokinetic (PBPK) modeling and quantitative systems pharmacology (QSP) integrate fine-level details of the kinetic or dynamic system. These models help improve the mechanistic understanding of a drug and support the discovery and early development of an NCE or NBE.
We hav performed model-based meta-analysis. MBMAs integrate large data from many sources to construct patterns (networks) based on a predictive model. MBMAs help support many aspects of decision making and planning in drug development. For example, one could use MBMA results to position a drug among its drug class or inform strategies for the development of a novel drug within a class.
Delphi Quantitative Sciences has not received any reviews.
Delphi Quantitative Sciences has not received any endorsements.